Comparative Pharmacology
Head-to-head clinical analysis: ERYTHROCIN STEARATE versus PEDIAMYCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ERYTHROCIN STEARATE versus PEDIAMYCIN.
ERYTHROCIN STEARATE vs PEDIAMYCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin binds to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis by blocking the translocation step. It may also act as a motilin receptor agonist, stimulating gastrointestinal motility.
Erythromycin is a macrolide antibiotic that binds to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis by blocking translocation of peptidyl-tRNA. It may be bacteriostatic or bactericidal depending on concentration and organism.
250-500 mg orally every 6 hours for mild to moderate infections; up to 4 g/day for severe infections.
250-500 mg orally every 6 hours; maximum 2 g/day.
None Documented
None Documented
1.5-2 hours in adults; prolonged to 5-6 hours in severe hepatic impairment. In anuria, half-life not significantly affected.
The terminal elimination half-life is approximately 1.5-2 hours in adults with normal renal function. In patients with severe hepatic impairment, half-life may be prolonged to 5-6 hours. The short half-life necessitates frequent dosing (every 6-8 hours) to maintain therapeutic levels.
Primarily biliary-fecal (90-95% as unchanged drug and metabolites); renal excretion accounts for 2-15%.
PEDIAMYCIN (erythromycin ethylsuccinate) is primarily excreted via the biliary route (60-70% as unchanged drug and metabolites) with significant fecal elimination. Renal excretion accounts for only 5-15% of the dose, mostly as inactive metabolites. Less than 5% is excreted unchanged in urine.
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic